These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
30 results:

  • 1. Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.
    Fujita KI; Matsumoto N; Murase R; Takeshima K; Ishida H; Kubota Y
    Clin Transl Sci; 2023 Oct; 16(10):1741-1747. PubMed ID: 37424405
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.
    Ye Y; Maroney KJ; Wiener HW; Mamaeva OA; Junkins AD; Burkholder GA; Sudenga SL; Khushman M; Al Diffalha S; Bansal A; Shrestha S
    Ann Med; 2023 Dec; 55(1):2199366. PubMed ID: 37177979
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Preclinical study of T cell receptor specifically reactive with
    Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
    Kim GB; Fritsche J; Bunk S; Mahr A; Unverdorben F; Tosh K; Kong H; Maldini CR; Lau C; Srivatsa S; Jiang S; Glover J; Dopkin D; Zhang CX; Schuster H; Kowalewski DJ; Goldfinger V; Ott M; Fuhrmann D; Baues M; Boesmueller H; Schraeder C; Schimmack G; Song C; Hoffgaard F; Roemer M; Tsou CC; Hofmann M; Treiber T; Hutt M; Alten L; Jaworski M; Alpert A; Missel S; Reinhardt C; Singh H; Schoor O; Walter S; Wagner C; Maurer D; Weinschenk T; Riley JL
    Sci Transl Med; 2022 Aug; 14(660):eabo6135. PubMed ID: 36044599
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
    J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
    Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
    J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant β-catenin signaling.
    Dabrowska M; Uram L; Dabrowski M; Sikora E
    Mech Ageing Dev; 2021 Jul; 197():111517. PubMed ID: 34139213
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Validation of immunogenic PASD1 peptides against hla-a*24:02 colorectal cancer.
    Soh JE; Abu N; Sagap I; Mazlan L; Yahaya A; Mustangin M; Khoo TS; Saidin S; Ishak M; Ab Mutalib NS; Jamal R
    Immunotherapy; 2019 Oct; 11(14):1205-1219. PubMed ID: 31478431
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
    Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
    Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
    Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
    Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
    Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
    Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
    Kijima T; Hazama S; Tsunedomi R; Tanaka H; Takenouchi H; Kanekiyo S; Inoue Y; Nakashima M; Iida M; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yamamoto S; Yoshino S; Okuno K; Nagano H
    Oncol Rep; 2017 Jan; 37(1):23-30. PubMed ID: 27878288
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
    McCann KJ; Mander A; Cazaly A; Chudley L; Stasakova J; Thirdborough S; King A; Lloyd-Evans P; Buxton E; Edwards C; Halford S; Bateman A; O'Callaghan A; Clive S; Anthoney A; Jodrell DI; Weinschenk T; Simon P; Sahin U; Thomas GJ; Stevenson FK; Ottensmeier CH
    Clin Cancer Res; 2016 Oct; 22(19):4827-4836. PubMed ID: 27091407
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
    Hazama S; Takenouchi H; Tsunedomi R; Iida M; Suzuki N; Iizuka N; Inoue Y; Sakamoto K; Nakao M; Shindo Y; Kanekiyo S; Tokumitsu Y; Yoshimura K; Maeda N; Maeda K; Maeda Y; Matsui H; Yoshino S; Nakamura Y; Fujita Y; Hamamoto Y; Okamoto M; Fujita T; Kawakami Y; Oka M
    Anticancer Res; 2014 Aug; 34(8):4201-5. PubMed ID: 25075047
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.
    Turcotte S; Katz SC; Shia J; Jarnagin WR; Kingham TP; Allen PJ; Fong Y; D'Angelica MI; DeMatteo RP
    Cancer Immunol Res; 2014 Jun; 2(6):530-7. PubMed ID: 24894090
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study).
    Hazama S; Nakamura Y; Tanaka H; Hirakawa K; Tahara K; Shimizu R; Ozasa H; Etoh R; Sugiura F; Okuno K; Furuya T; Nishimura T; Sakata K; Yoshimatsu K; Takenouchi H; Tsunedomi R; Inoue Y; Kanekiyo S; Shindo Y; Suzuki N; Yoshino S; Shinozaki H; Kamiya A; Furukawa H; Yamanaka T; Fujita T; Kawakami Y; Oka M
    J Transl Med; 2014 Apr; 12():108. PubMed ID: 24884643
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
    Oji Y; Tatsumi N; Fukuda M; Nakatsuka S; Aoyagi S; Hirata E; Nanchi I; Fujiki F; Nakajima H; Yamamoto Y; Shibata S; Nakamura M; Hasegawa K; Takagi S; Fukuda I; Hoshikawa T; Murakami Y; Mori M; Inoue M; Naka T; Tomonaga T; Shimizu Y; Nakagawa M; Hasegawa J; Nezu R; Inohara H; Izumoto S; Nonomura N; Yoshimine T; Okumura M; Morii E; Maeda H; Nishida S; Hosen N; Tsuboi A; Oka Y; Sugiyama H
    Int J Oncol; 2014 May; 44(5):1461-9. PubMed ID: 24589652
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dendritic cell-based immunotherapy for colon cancer using an hla-a*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
    Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
    Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
    Nobuoka D; Yoshikawa T; Takahashi M; Iwama T; Horie K; Shimomura M; Suzuki S; Sakemura N; Nakatsugawa M; Sadamori H; Yagi T; Fujiwara T; Nakatsura T
    Cancer Immunol Immunother; 2013 Apr; 62(4):639-52. PubMed ID: 23143746
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.